(Press-News.org) HOUSTON ― According to researchers at The University of Texas MD Anderson Cancer Center, 80% of patients with previously untreated or relapsed/refractory advanced-phase chronic myeloid leukemia (CML) – including both accelerated or myeloid blast phases of the disease – or Philadelphia chromosome-positive acute myeloid leukemia (AML) achieved a bone marrow remission when treated with a novel combination of decitabine, venetoclax and ponatinib.
Findings from the Phase II clinical trial, published today in The Lancet Haematology, represent an important step forward for patients with advanced-phase CML, who tend to have poor outcomes. Limited data on a standard-of-care approach to treating the disease, highlights the need for investigations into additional therapeutics.
“Over the last decade, there have been very few studies that evaluated a regimen to treat this rare disease and identify a potential standard-of-care treatment,” said principal investigator Nicholas Short, M.D., associate professor of Leukemia. “It is important that we get these patients into a state of marrow remission as this will allow them to be considered for a stem cell transplant. We were able to achieve this response in 80% of patients on this trial.”
A total of 20 patients were enrolled in the trial, with 14 having myeloid blast-phase CML, four with accelerated-phase CML, and two with Philadelphia chromosome-positive AML. Overall, 50% of patients achieved a complete remission or complete remission with an incomplete hematological recovery, and an additional 30% of patients achieved a morphologic leukemia-free state. Responses were seen even in patients who had received multiple prior therapies and in those with high-risk cytogenetic or molecular features.
“For this trial, we were able to build on previous preclinical and clinical research conducted at MD Anderson, which identified synergy between the BCL-2 inhibitor, venetoclax and the BCR::ABL1 tyrosine kinase inhibitor, ponatinib,” Short said. “This knowledge led us to consider this novel treatment regimen for this aggressive disease.”
The researchers observed expected side effects, which were consistent with previous studies with the drugs. Common side effects included neutropenia, rash and nausea.
The trial is ongoing and enrolling additional patients. MD Anderson researchers also are conducting additional studies building on the approach of adding targeted therapies into new combinations for patients with advanced-phase CML.
The trial was funded by Takeda Oncology, the National Institutes of Health and the National Cancer Institute Cancer Center Support Grant (P30 CA016672). A complete list of collaborating authors and their disclosures can be found here.
END
Novel triplet regimen yields promising response in advanced-phase chronic myeloid leukemia
Eighty percent of patients achieved complete remission when treated with decitabine, venetoclax and ponatinib in Phase II trial
2024-09-17
ELSE PRESS RELEASES FROM THIS DATE:
‘Scuba-diving’ lizards use bubble to breathe underwater and avoid predators
2024-09-17
BINGHAMTON, N.Y. -- Presenting the world’s smallest (and scrappiest) scuba diver: A species of semi-aquatic lizard produces a special bubble over its nostrils to breathe underwater and avoid predators, according to new research from Binghamton University, State University of New York.
Lindsey Swerk, an assistant research professor of biological sciences at Binghamton University, studies water anoles, a type of semi-aquatic lizard found in the tropical forests of southern Costa Rica. She had previously documented the lizards using a bubble underwater. When these lizards feel threatened by a predator, ...
USC launches large-scale nationwide study of type 1 diabetes and brain development
2024-09-17
About half of adults with type 1 diabetes face significant cognitive impairment, including problems with working memory and executive function that affect day-to-day thinking. But less is known about how the condition affects children during a window of time known to be critical for healthy brain development.
A new large-scale longitudinal study, led by the Keck School of Medicine of USC, will unite 12 research centers across the United States to explore that important question. Researchers will collaborate to recruit a large, diverse group of children newly diagnosed with diabetes, taking a sweeping look at the environmental, lifestyle, ...
Ancestry-specific genetic variants linked to multiple sclerosis risk, new study shows
2024-09-17
A landmark study has uncovered novel ancestry-specific genetic variants linked to multiple sclerosis (MS), offering new insights that could reshape treatment approaches for diverse populations affected by the disease.1 The research, presented today at ECTRIMS 2024, is the result of efforts by the Alliance for Research in Hispanic MS (ARHMS) Consortium and is the first large-scale study to identify ancestry-specific genetic effects for MS risk.
In a comprehensive analysis of over 7,000 individuals from self-reported Hispanic (n=4,313; 2,201 MS, 2,112 controls) and African American (n=3,085; 1,584 MS, 1,501 controls) backgrounds, researchers discovered ...
Early high-efficacy treatment significantly reduces long-term disability in children with multiple sclerosis, new study finds
2024-09-17
New research presented today at ECTRIMS 2024 reveals that initiating monoclonal antibody therapy during childhood, rather than delaying treatment until early adulthood, significantly reduces long-term disability in multiple sclerosis (MS) patients.1
The study, which utilised data from the French MS Registry, Italian MS Register, and the global MSBase Registry, analysed the outcomes of 282 patients with paediatric-onset MS who began experiencing symptoms before the age of 18 years. Patients were divided into two groups based on when they initiated monoclonal antibody treatment: either ...
Terasaki Institute CEO Dr. Ali Khademhosseini awarded the AIChE’s 2024 Andreas Acrivos Professional Progress
2024-09-17
Dr. Ali Khademhosseini, Ph.D., CEO and Director of the Terasaki Institute for Biomedical Innovation (TIBI), is honored with the 2024 Andreas Acrivos Award for Professional Progress in Chemical Engineering by the American Institute of Chemical Engineers (AIChE). This distinguished honor recognizes outstanding progress in the field of chemical engineering.
Named after Dr. Andreas Acrivos, Albert Einstein Professor of Science and Engineering, emeritus at the City College of New York, whose pioneering work in fluid ...
Slow-moving landslides a growing, but ignored, threat to mountain communities
2024-09-17
American Geophysical Union
17 September 2024
AGU Release 24-33
For Immediate Release
This press release is available online at: https://news.agu.org/press-release/slow-landslides-growing-threat-mountain-communities/
Slow-moving landslides a growing, but ignored, threat to mountain communities
Urban growth, climate change, and flood risk at lower elevations can push people to live on steeper, more dangerous terrain
AGU press contact:
Rebecca Dzombak, news@agu.org (UTC-4 hours)
Potsdam press contact:
Stefanie Mikulla, University of Potsdam, presse@uni-potsdam.de (UTC+2 hours)
Researcher contact:
Joaquin Vicente Ferrer, ...
Study finds thousands of browser extensions compromise user data
2024-09-17
Browser extensions, the software add-ons that help users customize and enhance their web browsers, are wildly popular. Some of the most-used extensions find shopping deals, fix grammar and typos, manage passwords, or translate web pages. The types of extensions available are nearly endless, and many have become indispensable tools for businesses and everyday users.
While these extensions can make web browsing more accessible, productive, and rewarding, they are not without risk. New research from Georgia Tech reveals that thousands of browser extensions pose significant threats to privacy, and hundreds automatically ...
Building better DNA editors: Retrons raise the bar for gene research
2024-09-17
SAN FRANCISCO—Within bacterial cells, specialized immune systems known as retrons fend off viral attacks. But that’s not all they can do.
Scientists, including Seth Shipman, PhD, at Gladstone Institutes, have shown that retrons also serve an important purpose in the lab: precise DNA editing. In fact, retrons can be combined with CRISPR—the far more famous bacterial-defense-system-turned-gene-editor—to better edit human cells.
Yet, for all their potential to help scientists better understand disease and develop new therapies, only a small number of retrons have been studied. In nature, many thousands of variations exist, some with greater gene-editing powers than ...
Study shows SIM models improve health data
2024-09-17
First-of-its-kind research by Tarang Parekh, assistant professor of epidemiology, reviewed the State Innovation Models (SIM), a payment system introduced by the Centers for Medicare and Medicaid Services in 2013, which provides financial incentives to states to develop innovative payment models to improve healthcare systems.
In the study, recently published in the American Journal of Epidemiology, Parekh compared data from 2010 to 2015 from three SIM participating states, Arkansas, Massachusetts and Vermont, to Florida, Nebraska and New Mexico, which do not participate in ...
Study suggests humor could help people engage with colorectal cancer information
2024-09-17
BUFFALO, N.Y. – Colorectal cancer (CRC) is no laughing matter. It’s the second-leading cause of cancer deaths globally, according to the World Health Organization. But new research led by the University at Buffalo suggests that humor can be an effective mechanism for reaching people who otherwise avoid information about colorectal cancer screening or other health messaging.
The research, published online ahead of print in the British Journal of Health Psychology, found that in people who demonstrated a ...
LAST 30 PRESS RELEASES:
Researchers generate lung cells from mouse fibroblasts in just 7 to 10 days
Prizewinner’s research reveals how immune responses to friendly skin microbiota could pave way for novel vaccination responses
Old aerial photos give scientists a new tool to predict sea level rise
20 million for courageous research at ISTA
Ships trigger high and unexpected emissions of the greenhouse gas methane
Optimizing laser irradiation: An in-silico meta-analysis of skin discoloration treatment
Climate crisis could force wild vanilla plants and pollinating insects apart, threatening global supply
Teens report spending 21% of each driving trip looking at their phone
Study explores the ‘social norms’ of distracted driving among teens
Diver-operated microscope brings hidden coral biology into focus
Enhancing the “feel-good” factor of urban vegetation using AI and street view images
A single genetic mutation may have made humans more vulnerable to cancer than chimpanzees
Innovative nanocomposite hydrogel shows promise for cartilage regeneration in osteoarthritis treatment
2025 Guangci Laboratory Medicine Innovation and Development Conference
LabMed Discovery is included in the ICI World Journals database
LabMed Discovery is included in the China Open Access Journal (COAJ) database
Vaccination support program reduces pneumonia-related mortality by 25 percent among the elderly
Over decades, a healthy lifestyle outperforms metformin in preventing onset of Type 2 diabetes
Mental health disorders, malaria, and heart disease most affected by covid pandemic
Green transition will boost UK productivity
Billions voted in 2024, but major new report exposes cracks in global democracy
Researchers find “forever chemicals” impact the developing male brain
Quantum leap in precision sensing across technologies
Upgrading biocrude oil into sustainable aviation fuel using zeolite-supported iron-molybdenum carbide nanocatalysts
For effective science communication, ‘just the facts’ isn’t good enough
RT-EZ: A golden gate assembly toolkit for streamlined genetic engineering of rhodotorula toruloides
Stem Cell Reports announces five new early career editors
Support networks may be the missing link for college students who seek help for excessive drinking
The New England Journal of Medicine shines spotlight on forensic pathology
Scientists discover protein that helps lung cancer spread to the brain
[Press-News.org] Novel triplet regimen yields promising response in advanced-phase chronic myeloid leukemiaEighty percent of patients achieved complete remission when treated with decitabine, venetoclax and ponatinib in Phase II trial